Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases [3][4] - The company's lead product candidate, DURAVYU™, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [3][5] - EyePoint has a history of four approved drugs over three decades and has treated tens of thousands of eyes with its innovations [4] Product Development - DURAVYU™ is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration, with topline data expected in mid-2026 [3] - The first patient dosing in the pivotal Phase 3 clinical trials for diabetic macular edema is anticipated in the first quarter of 2026 [3] Corporate Events - George O. Elston, Executive Vice President and Chief Financial Officer of EyePoint, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [1] - A webcast and archived replay of the fireside chat will be available on the company's website [2]

Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases, with a commitment to improving patient lives [3][4] - The company will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 [1] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company with a lead product candidate, DURAVYU, which is a sustained delivery treatment for VEGF-mediated retinal diseases [3] - DURAVYU combines vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E technology [3] - The company is currently evaluating DURAVYU in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD), with topline data expected in 2026 [3] - DURAVYU has also completed a positive Phase 2 clinical trial in diabetic macular edema (DME), with Phase 3 planning underway [3] - Despite existing therapies, patients with wet AMD and DME continue to experience long-term vision loss, with wet AMD being the leading cause of vision loss in individuals aged 50 and older in the U.S. [3] Product and Development - Vorolanib is exclusively licensed to EyePoint for the localized treatment of all ophthalmic diseases outside of specific regions in Asia [5] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, although it has not yet received FDA approval [5]